Vertex Pharmaceuticals Stock Performance
VRTX Stock | USD 418.01 0.69 0.17% |
Vertex Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The entity has a beta of 0.54, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Vertex Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Vertex Pharmaceuticals is expected to be smaller as well. Vertex Pharmaceuticals right now has a risk of 1.19%. Please validate Vertex Pharmaceuticals value at risk, kurtosis, price action indicator, as well as the relationship between the semi variance and rate of daily change , to decide if Vertex Pharmaceuticals will be following its existing price patterns.
Risk-Adjusted Performance
2 of 100
Low | High |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Vertex Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Vertex Pharmaceuticals is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.17 | Five Day Return 0.0622 | Year To Date Return 1.73 | Ten Year Return 491.08 | All Time Return 9.2 K |
Last Split Factor 2:1 | Last Split Date 2000-08-24 |
1 | Reasons to Invest in Vertex Pharmaceuticals Incorporated | 03/04/2024 |
2 | Verato Enables Healthcare to Know Who is Who with Google Cloud | 03/13/2024 |
3 | Vertex Pharmaceuticals Beats Stock Market Upswing What Investors Need to Know | 03/18/2024 |
4 | Orca Security Adds AI Security to Cloud Security Platform | 03/19/2024 |
5 | 3 Biopharma Stocks Predicted to Soar in Q2 2024 | 03/20/2024 |
6 | Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease | 03/21/2024 |
7 | Vertex Pharmaceuticals Rises As Market Takes a Dip Key Facts | 03/25/2024 |
8 | Mercks next big thing is on the way | 03/26/2024 |
9 | Vertex trust sells over 820k in company stock | 03/28/2024 |
Begin Period Cash Flow | 10.5 B |
Vertex |
Vertex Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 41,091 in Vertex Pharmaceuticals on December 30, 2023 and sell it today you would earn a total of 710.00 from holding Vertex Pharmaceuticals or generate 1.73% return on investment over 90 days. Vertex Pharmaceuticals is currently generating 0.0351% in daily expected returns and assumes 1.1887% risk (volatility on return distribution) over the 90 days horizon. In different words, 10% of stocks are less volatile than Vertex, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Vertex Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vertex Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vertex Pharmaceuticals, and traders can use it to determine the average amount a Vertex Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0295
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | VRTX |
Estimated Market Risk
1.19 actual daily | 10 90% of assets are more volatile |
Expected Return
0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Vertex Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vertex Pharmaceuticals by adding it to a well-diversified portfolio.
Vertex Pharmaceuticals Fundamentals Growth
Vertex Stock prices reflect investors' perceptions of the future prospects and financial health of Vertex Pharmaceuticals, and Vertex Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vertex Stock performance.
Return On Equity | 0.23 | ||||
Return On Asset | 0.13 | ||||
Current Valuation | 97.43 B | ||||
Shares Outstanding | 258.31 M | ||||
Price To Earning | 24.57 X | ||||
Price To Book | 6.13 X | ||||
Price To Sales | 10.92 X | ||||
Revenue | 9.84 B | ||||
Gross Profit | 5.32 B | ||||
EBITDA | 3.93 B | ||||
Net Income | 3.62 B | ||||
Cash Per Share | 38.06 X | ||||
Debt To Equity | 0.06 % | ||||
Current Ratio | 4.70 X | ||||
Cash Flow From Operations | 3.54 B | ||||
Earnings Per Share | 13.90 X | ||||
Total Asset | 22.73 B | ||||
Retained Earnings | 10.14 B | ||||
Current Asset | 1.41 B | ||||
About Vertex Pharmaceuticals Performance
To evaluate Vertex Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Vertex Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Vertex Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Vertex Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Vertex's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for 2024 | ||
Return On Capital Employed | 0.20 | 0.21 | |
Return On Assets | 0.16 | 0.17 | |
Return On Equity | 0.21 | 0.22 |
Things to note about Vertex Pharmaceuticals performance evaluation
Checking the ongoing alerts about Vertex Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vertex Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Vertex Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
Over 96.0% of the company outstanding shares are owned by institutional investors | |
Latest headline from investing.com: Vertex trust sells over 820k in company stock |
- Analyzing Vertex Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vertex Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Vertex Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vertex Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vertex Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vertex Pharmaceuticals' stock. These opinions can provide insight into Vertex Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Transaction History View history of all your transactions and understand their impact on performance | |
Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.9 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.